Active	Status	Sponsor type	Region	Phase	Filter
3 Active 3 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ribrecabtagene autoleucel (DRL-1801) / Dr. Reddy’s, Galapagos
NCT06497387: Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease	Recruiting	1	30	RoW	PRG-1801	Tongji Hospital, Shenzhen Pregene Biopharma Co., Ltd.	Lupus Nephritis, IgG4-related Disease	07/27	07/28
NCT06519565: Safety and Efficacy of PRG-1801 in Recurrent/Refractory Immune Thrombocytopenia (ITP)	Recruiting	1	9	RoW	PRG-1801, BCMA-targeting CAR-T Cells	Wuhan Union Hospital, China, Shenzhen Pregene Biopharma Co., Ltd.	Immune Thrombocytopenia	08/25	08/27
NCT06277427: Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells	Recruiting	N/A	24	RoW	PRG-1801 （CAR-T against BCMA）	Lingli Dong, Shenzhen Pregene Biopharma Co., Ltd.	Lupus Nephritis, ANCA Associated Vasculitis	02/26	01/27